BIO

He holds MD and PhD degrees at Baylor College of Medicine in Houston, TX, where his research focused on immunotherapy for hepatitis B virus. Dr. Kruse has a long-standing interest in cell and gene therapy with multiple patents in the field, including a foundational patent in circular mRNA field.

Dr. Kruse with his co-founders worked together on the gene delivery technology underlying HydroGene during their time at Johns Hopkins. They are proud alums of the Nucleate Bio program, winning the Baltimore chapter pitch competition in 2022. HydroGene also participated in the Texas Medical Center Innovation’s Accelerator for Cancer Therapeutics in 2023.

Beyond research, Dr. Kruse is also a practicing transfusion medicine physician, having previously trained at Johns Hopkins and Harvard for residency and fellowship, respectively. He was selected by the American Society of Clinical Pathology as a 40 under 40 honoree in 2021.